

HBPSURGERY WEEK2022

Review of Various Hemostatic Materials for Liver Resection

Dai Hoon Han

Department of HBP surgery, Yonsei University College of Medicine

HBPSURGERY WEEK2022

Conflict of interest

Nothing to declare.

Mortality after liver resection in the history

HBPSURGERY WEEK2022




FIGURE 1 Variations in hepatectomy-related mortality, according to data from a nationwide follow-up study conducted by the Liver Cancer Study Group of Japan. In Japan, surgery-related mortality after liver cancer resection exceeded 15% in the 1970s, but decreased rapidly in the 1980s and reached a level as low as approximately 1% in the late 1990s¹²

Kokudo, Ann Gastroenterol Surg. 2020

Bleeding in the history of liver surgery

HBPSURGERY WEEK2022

Hepatic Lobectomy

HARTIN A. ADSON, MD, AND ROBERT R. JONES, MD, ROCHESTER, MINN. Saturday, Nov 20, 1965

TABLE 1.—Total Removal of Right or Left Hepatic Lobe in Patients With Primary Hepatic Malignant Lesions

Case	Age, Yr; Sex	Type and Grade of Lesion	Resection		Transfusion, ml	Days in Hospital	Follow-Up
			Extent	Amount, Gm			
1	38, M	Hepatoma, malignant, grade 1	Left total lobectomy + gallbladder	770	18,750 *	26	Living, no evidence of recurrence, 4 years postoperatively
2	48, F	Multifocal papillary carcinomatous, grade 2	Left total lobectomy	1	1,800	13	Living, no evidence of recurrence, 4 years postoperatively
3	40, F	Hepatoma, malignant, grade 1	Left total lobectomy	2,800	11,800 *	27	Died, 3 1/2 years postoperatively; lung & bone metastases
4	40, F	Hepatoma, malignant, grade 1	Right total lobectomy + gallbladder	1,230	6,900	38	Living, no evidence of recurrence, 2 1/2 yr postoperatively
5	18, M	Hepatoma, malignant, grade 2	Left total lobectomy + part of right hepatic duct	330	5,800	13	Living, no evidence of recurrence, 1 1/2 years postoperatively
6	34, F	Hepatoma, malignant, grade 4	Right total lobectomy + anterior medial segment of left lobe + gallbladder + part of diaphragm	1,800	13,000 *	13	Died, 2 1/2 months postoperatively

* The anatomic factor responsible for the problem in hemostasis is described in the text.
† Weight unknown; normal specimen was 20 cm in diameter.

Archives of Surgery, 1966

Bleeding in the history of liver surgery

HBPSURGERY WEEK2022

Hepatic Lobectomy

HARTIN A. ADSON, MD, AND ROBERT R. JONES, MD, ROCHESTER, MINN. Saturday, Nov 20, 1965

TABLE 2.—Total Removal of Right or Left Hepatic Lobe in Patients With Benign or Metastatic Hepatic Lesions


Case	Age, Yr; Sex	Type and Grade of Lesion	Resection		Transfusion, ml	Days in Hospital	Follow-Up
			Extent	Amount, Gm			
7	35, F	Benign, nonspecific, nodular atrophy	Right total lobectomy + gallbladder	800	5,000	12	Living and well, 1 1/2 years postoperatively
8	46, M	Colonic carcinoma, grade 2 (1 year) *	Right total lobectomy + part of diaphragm + gallbladder	1,150	3,800	40	Died, 30 months postoperatively
9	40, F	Colonic carcinoma, grade 2 (2 year) *	Right total lobectomy + right adrenal + gallbladder	2,300	3,500	22	Died, 10 months postoperatively
10	26, M	Colonic carcinoma, grade 3 (hypohemostasis)	Right total lobectomy + right colon + gallbladder	1,900	6,000		Died, 17 days postoperatively
11	40, M	Carcinoid, ileum (10 weeks) *	Right total lobectomy + gallbladder	1,000	16,000 †	29	Living and well, 7 months postoperatively; carcinoid syndrome relieved

* Interval since previous resection.
† The anatomic factor responsible for the problem in hemostasis is described in the text.

Archives of Surgery, 1966







Improved hemostasis with major hepatic resection in the current surgical era



HBPSURGERY WEEK2022



Current surgical era

Mangieri, Hepatobiliary Pancreat Dis Int, 2020





- Topical hemostats** HBP SURGERY WEEK 2022
- ❖ Passive mechanical
 - No coagulation factors
 - ❖ Active non-mechanical
 - Contain coagulation factors
 - ❖ Active sealants (fibrin sealants)
 - Contain coagulation factors
 - ❖ Passive sealants (synthetic and semi-synthetic glues and adhesives)
 - No coagulation factors


- Topical hemostats** HBP SURGERY WEEK 2022
- ❖ Passive mechanical
 - Most effective for small amounts of bleeding
 - Do not contain any active biological substances to promote coagulation
 - Made from substances such as cellulose, collagen and gelatin
 - Provide a mechanical barrier to blood and a matrix for platelet adhesion and aggregation
 - Risks: swelling of the material can cause nerve or tissue injury especially in closed areas such as the orbit, cranium or spine




- Topical hemostats** HBP SURGERY WEEK 2022
- ❖ Active non-mechanical
 - contain thrombin and are topically applied to the wound to promote coagulation
 - Effectiveness of thrombin can be enhanced by applying the product with an absorbable porcine gelatin in the form of a sponge or powder to which manual pressure can be applied
 - In the case of thrombin-coated granules (e.g. FloSeal), the product also acts as a site for platelet aggregation
 - Risks: immune-mediated coagulopathy. Thrombins should never be administered intramuscularly – associated with shock and massive intravascular thrombosis

Topical hemostats

❖ Active non-mechanical




Floseal




Surgiflo

Floseal; Surgiflo: absorbable gelatin with thrombin




EVITHROM

Evithrom: human thrombin



Thrombin JMI: bovine thrombin



Recothrom: recombinant thrombin


Topical hemostats

❖ Active sealing (fibrin sealants)


- contain the active substances thrombin and fibrinogen which, when combined, form fibrin
- the fibrin cross links directly with exposed tissue collagen to anchor tissues and clots to wound surfaces
- Typically a flowable product that is topically applied to the bleeding site
- As they are flowable, these products do not offer immediate mechanical support
- Risks: excessively thick layers lead to poor healing and infection; air embolism, risk of swelling and coagulopathy

Topical hemostats


❖ Active sealing (fibrin sealants)




Beriplast



Evicel



Tisseel




Greenplast


Topical hemostats

❖ Passive hemostatic sealants/glues

- During surgery, in addition to blood loss, leakage of bile, lymph, urine, CSF and air may also occur. Synthetic or semi-synthetic glues can be used to help seal such leaks
- They create a physical seal and do not contain any clotting factors
- Products in this class **do not clot blood**



BioGlue: glutaraldehyde and bovine serum albumin



HemoPatch: collagen patch coated with NHS-PEG (also mechanical support)

Topical hemostats

Topical haemostats			Topical haemostatic sealants and (semi-) synthetic sealants	
Passive	Active		Active	Passive
Recombinant factors (Beriplast)	Coagulation factors (Fibrinogen)		Fibrin sealants (Evicel, Beriplast)	Semi-synthetic sealants (BioGlue, HemoPatch)
Surgical TachoSeal	Floseal		Beriplast	Cofaseal
TissuFloc	Surgiflo		Quixil	DuraSeal
Surgifoam	Evithrom		Evicel	VasculSeal
Artisal Haemostase	Recothrom (Recombinant)		Tisseel/Tissucol	TissuePatch (Also mechanical support)
Instal MCH	Thrombin JMI (also with)		Vivostat	BioGlue
Avitane				Hemopatch (Also mechanical support)
Lysostyl				Veripatch (Also mechanical support)
Spongeson				
TachoTop				

TachoSil®

Active Haemostat and Sealant Patch

Bioactive coagulation factors + sealing and mechanical support

TachoSil® bridges the gap

TachoSil®

- Bleeding and fluid leaks remain technical challenges in surgery
- Insufficient haemostasis and tissue sealing may contribute to post-operative morbidity and mortality
- TachoSil® is indicated in adults for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing, and for suture support in vascular surgery where standard techniques are insufficient
- TachoSil® may help reduce the risk of bleeding complications while being cost-effective

TachoSil®

HBP SURGERY WEEK 2022


Products	Active	Mechanical	Sealant
Surgicel, TissuFleece, Lysostypt, Arista, Instat MCH, Avitene, Surgifoam, Spongostan, Veriset		✓	
FloSeal, Surgiflo, Evithrom, Recothrom, Thrombin JMI	✓		
Beriplast, Evicel, Tisseel, Quixil, Vivostat	✓		✓
Hemopatch		✓	✓
CoSeal, DuraSeal, VascuSeal, BioGlue			✓
TachoSil	✓	✓	✓

TachoSil® ticks every category

TachoSil® : physical characteristics

HBP SURGERY WEEK 2022


- TachoSil® combines the bioactive mechanism of action of human fibrinogen and thrombin for haemostasis and tissue sealing, with the mechanical support of a collagen patch
- TachoSil® is classified as a local hemostat



TachoSil® : physical characteristics
- the passive part

HBP SURGERY WEEK 2022

- The passive part of TachoSil® is a collagen patch composed of closed honeycomb-like cells with a weight of 1.3-2.0 mg/cm²




Scanning electron microscopy

TachoSil® : physical characteristics
-the active part

HBP SURGERY WEEK 2022


- The active side of the collagen patch is uniformly coated with coagulation factors and marked yellow with riboflavin




Scanning electron microscopy (x 1200)

TachoSil® : physical characteristics
-unique properties create a strong seal

HBP SURGERY WEEK 2022




- Fibrinogen and thrombin is embedded in the open cells on the surface of the collagen sponge
- Upon contact with blood or other body fluids the coagulation factors thrombin and fibrinogen are activated
- Activation of the coagulation factors and the collapse, not destruction, of the collagen cells conglutinate the TachoSil® patch with the tissue surface
- A seal is created between collagen patch and tissue



TachoSil® : physical characteristics
-tensile capability

HBP SURGERY WEEK 2022


- The proven pliability of TachoSil® ensures that it can be safely applied to moving organs such as heart, lungs and vessels — and stays in place while remaining intact




TachoSil® under stretch

TachoSil® : physical characteristics
-adhesive strength testing

HBP SURGERY WEEK 2022



Pressure chamber Porcine pleura with 10 mm hole Hole sealed with TachoSil® Pressure applied



Pressure chamber with flanged porcine pleura with defect (10 mm diameter). Leak closed with 30 mm diameter TachoSil® patch. Pressure is applied via the pressure chamber until the patch lifts from the tissue. TachoSil® shows good adhesive strength – the maximum pressure tolerated was double that of TissuFleece (see next slide)


Proven: TachoSil® has adhesive strength to stay in place

TachoSil® : physical characteristics
-adhesive strength comparisons

HBP SURGERY WEEK 2022

- The adhesive strength of TachoSil® is superior to other sealants.
- TachoSil® has been tested for adhesive strength in various body fluids.

	Mean maximum pressure tolerated (hPa)
Beriplast	8.2
Soft PGA Felt	14.4
Tachotop	19.2
TissuFleece E	30.7
TachoComb	59.7
TachoComb H	57.5
TachoSil (TachoComb S)	61.4




hPa

Sealant: Beriplast, Soft PGA Felt, Tachotop, TissuFleece E, TachoComb, TachoComb H, TachoSil (TachoComb S), Plasma available, Urine, Blood, Cystic, Lymph, Arterial, Peritoneal (dog or monkey), Gastric, Pleurothoracic cavity (TachoComb S)

TachoSil® : physical characteristics
-encourages natural wound healing

HBP SURGERY WEEK 2022

- Wound healing starts with haemostasis
- Blood cells (platelets) migrate to the wound/TachoSil® area
- Fibrin formed from fibrinogen provides a framework for the next stage of healing
- Blood cells secrete chemicals which attract collagen-secreting cells to the area
- Granulation tissue is formed from collagen, providing a scaffold for further tissue remodelling and scar formation



liver parenchyma collapsed collagen cells


Scanning electron microscopy

fibrin clot
Deposition of a fibrin clot formed from the fibrinogen and thrombin in TachoSil® causes haemostasis and conglutination of the patch to the wound.

TachoSil® : physical characteristics
-advantages

HBP SURGERY WEEK 2022

- TachoSil® can offer haemostasis in just three minutes^{1,2}
- TachoSil® can be stored at room temperature for three years, ready to use when needed³
 - No thawing or defrosting
 - No mixing or other preparation before use
- TachoSil® can even be applied on moving organs⁴
 - TachoSil® can be cut to shape and applied wet or dry
 - TachoSil® moulds with the organ surface
- Can be applied to a bleeding/leaking surface³
 - Many other products need a dry surface to work
 - TachoSil® is not "washed away"



1. Miesner F, Kasper H, Bismuth H, et al. TachSil surgical patch versus conventional haemostatic foam material for control of bleeding in cardiovascular surgery: a randomised controlled trial. Eur Cardiothorac Surg. 2009; 36:706–714.

2. Jellison B et al. Efficacy and safety of TachSil as haemostatic treatment versus standard suturing in kidney tumour resection: a randomised prospective study. Eur J End Urol. 2017; 22:1154-1162.

3. TachSil® Data Sheet

4. Carlson RT. Evaluation of Surgicel® fibrin-based sealing: history, material science, and clinical application. In: Landerwasser K, Wiles DB, Toppin DJ, Greenlee JG, Vessely RB, Hunsell DC, eds. Surgicel and Clinical Applications. Medical Devices Inc. 2002: 397-400.

Evolution of TachoSil®

HBP SURGERY WEEK 2022

- TachoComb® was developed in Germany and first launched in 1992
- TachoSil® was subsequently launched in 2004


TachoComb®	TachoComb H®	TachoSil®
Human fibrinogen Bovine thrombin Bovine aprotinin Equine collagen	Human fibrinogen Human thrombin Bovine aprotinin Equine collagen	Human fibrinogen Human thrombin Equine collagen

No bovine components

TachoSil® in hepatic surgery
- rapid haemostasis during liver resection

HBP SURGERY WEEK 2022

- The mean time to haemostasis was 1.4 minutes quicker with TachoSil® (3.6 min vs. 5 min, $p=0.018$).
- In some patients the difference was as great as 5 minutes in favour of TachoSil®.
- While TachoSil® application requires pressure and ABC does not, all resection procedures included application of pressure before other means of haemostasis.
- Compared with ABC, TachoSil® may offer a cost-saving, but this was not assessed in this study.



Time to haemostasis

Time (minutes)

TachoSil ABC

TachoSil can be recommended as a valuable tool for achieving standardised and fast haemostasis after liver resection.

Fischer L et al 2011

TachoSil® in hepatic surgery

- reduction in postoperative complications

HBP SURGERY WEEK 2022

Briceño J et al. A prospective study of the efficacy of clinical application of a new carrier-bound fibrin sealant after liver resection. Arch Surg 2010;145:482-88

- 115 patients undergoing conventional liver resection. Patients were randomised to have:
 - One or more TachoSil® patches applied to the raw surface of the liver (n=57)
 - Receive no haemostatic product (control group, n=58)
- TachoSil® decreased the mean drainage volume (691.2 ml vs. 1124.7 ml in the control group) (p=0.007)
- TachoSil® was also associated with a reduction in requirements for blood transfusion (7.0% of TachoSil® patients vs. 18.9% of control patients) (p=0.04)
- There were fewer significant postoperative complications (such as bile leaks) in the TachoSil® group (8% of patients vs. 21% of control patients) (p=0.03)
- The mean length of hospital stay was 9.6 days for patients receiving TachoSil® vs. 12.6 days for the control group (p=0.03) which has a positive impact on hospital budget


TachoSil® in hepatic surgery

- reduced bile leakage in split liver transplantation

HBP SURGERY WEEK 2022

Toti L et al. Reduction in bile leaks following adult split liver transplant using a fibrin-collagen sponge: A pilot study. Digestive and Liver Disease 2010; 42: 205-209

- The study assessed the effect of treatment of the cut surface of the graft with TachoSil® (n=16) to seal vessels, compared with the use of fibrin glue (n=16)
- Post-operative bile leakage was less common in the TachoSil® group: 1 (6.25%) TachoSil® patient vs. 7 (43.75%) fibrin glue patients, p=0.03



Intra-operative view after application of TachoSil® to the cut liver surface

HBP SURGERY WEEK 2022

Thank you for your kind attention.